摘要
目的探讨将利拉鲁肽、甘精胰岛素相结合作为2型糖尿病(Type 2 Diabetes Mellitus,T2DM)伴肥胖者治疗方案对患者体质指数(Body Mass Index,BMI)、血糖、胰岛功能影响。方法选取2022年1月—2023年10月宝应县中医医院收治的80例T2DM伴肥胖患者为研究对象,采取随机分组法分为观察组和对照组,各40例。对照组以单纯甘精胰岛素进行治疗,观察组以利拉鲁肽联合甘精胰岛素进行治疗。两组患者均干预3个月,比较干预前后两组BMI、血糖指标[空腹血糖(Fasting Blood Glucose,FPG)、餐后2 h血糖(2 h Postpran-dial Blood Glucose,2 hPG)、糖化血红蛋白(Glycosylated Hemoglobin,HbA1c)]、胰岛功能[胰岛素抵抗指数(Homeostasis Model Assessment of Insulin Resistance Inde,HOMA-IR)]变化。结果干预前,对比两组BMI、血糖及HOMA-IR指标,差异无统计学意义(P均>0.05);干预3个月观察组患者BMI(23.15±1.25)kg/m^(2)、FPG(6.02±0.84)mmol/L、2 hPG(7.25±1.12)mmol/L、HbA1c(4.85±0.62)%、HOMA-IR(3.42±0.52)都明显比对照组低,差异有统计学意义(P均<0.05)。结论T2DM伴肥胖者的治疗,采用利拉鲁肽、甘精胰岛素协同方式干预,可以取得满意的干预效果,明显降低BMI,有利于血糖控制以及调节胰岛功能指标。
Objective To investigate the effects of combining liraglutide and glargine insulin as a therapeutic regimen for type 2 diabetes mellitus(T2DM)with obesity on patients'body mass index(BMI),blood glucose,and pancreatic is-let function.Methods A total of 80 cases of T2DM with obesity admitted to Baoying County Hospital of Traditional Chinese Medicine from January 2022 to October 2023 were selected as the study objects and were divided into the ob-servation group and the control group by the randomized grouping method,with 40 cases in each group.The control group was treated with simple glargine insulin,while the observation group was treated with liraglutide combined with glargine insulin.Both groups were intervened for 3 months,and the changes of BMI,blood glucose indexes[fasting glucose(FPG),2 h postprandial glucose(2 hPG),glycated hemoglobin(HbA1c)],and pancreatic function[Homeostasis Model Assessment of Insulin Resistance Index(HOMA-IR)]were compared between the two groups before and after the intervention.Results Before intervention,there were no differences in BMI,blood glucose and HOMA-IR indexes between the two groups(all P>0.05).BMI(23.15±1.25)kg/m^(2),FPG(6.02±0.84)mmol/L,2 hPG(7.25±1.12)mmol/L,HbA1c(4.85±0.62)%,and HOMA-IR(3.42±0.52)of the patients in the observation group after the 3 months of inter-vention were significantly lower than those in the control group,and the differences were significantly significant(all P<0.05).Conclusion The treatment of T2DM with obesity,the use of liraglutide,glargine insulin synergistic approach to intervention,can achieve a satisfactory intervention effect,significantly reduce the BMI,is conducive to glycemic control as well as regulate the islet function index.
作者
于建勇
YU Jianyong(Baoying County Hospital of Traditional Chinese Medicine,Yangzhou,Jiangsu Province,225800 China)
出处
《糖尿病新世界》
2024年第5期28-31,共4页
Diabetes New World Magazine
关键词
2型糖尿病
肥胖
利拉鲁肽
甘精胰岛素
体质指数
血糖
胰岛功能
Type 2 diabetes mellitus
Obesity
Liraglutide
Glargine insulin
Body mass
Blood glucose
Pancreatic islet function
